JOHNSON & JOHNSON LEVAQUIN SALES DOWN
14 Oct
According to Johnson & Johnson’s third quarter financial results: Sales of Levaquin our anti-infective were down 5.7% on an operational basis when compared to the same period a year ago. Total prescriptions in the US anti-infective market are estimated to be up slightly in the quarter.
This is indicative of a decrease in prescriptions and use. Let’s keep spreading the word of the dangers associated with this drug until it is off the market.
No comments yet